ORIGINAL PAPER
Urinary trypsin inhibitor: anti-inflammatory effects in septic mice and molecular insights in bacterial lipoprotein-induced THP-1 cells
,
 
,
 
,
 
,
 
 
 
More details
Hide details
1
Department of Geriatrics Intensive Care Unit, Critical Care Center, The First Affiliated Hospital with Nanjing Medical University, China
 
 
Submission date: 2024-04-12
 
 
Final revision date: 2024-09-11
 
 
Acceptance date: 2024-09-30
 
 
Publication date: 2025-07-10
 
 
Cent Eur J Immunol 2025;(2):210-218
 
KEYWORDS
ABSTRACT
Introduction:
Excessive release of inflammatory cytokines in severe infections significantly contributes to the onset and progression of sepsis, a condition linked to elevated mortality rates in intensive care units. However, the lack of effective sepsis treatment strategies remains a significant challenge in critical care medicine. The use of anti-inflammatory agents against sepsis has advantages. Urinary trypsin inhibitor (UTI), a serine protease inhibitor obtained from the urine of healthy males, finds broad application in patients with inflammatory conditions such as shock, pancreatitis, and trauma. This investigation aimed to examine the impact and underlying mechanism of UTI in mice with sepsis and THP-1 cells stimulated by bacterial lipoprotein (BLP).

Material and methods:
C57BL/6J mice were divided into the control, sham operation, cecal ligation and puncture (CLP), and UTI + CLP groups. Histological staining was performed to assess heart and lung injury. Transmission electron microscopy was performed to analyze myocardial mitochondrial injury. The creatine kinase-myoglobin binding and aspartate aminotransferase isoenzyme were detected by evaluating heart injury. Serum interleukin 1β (IL-1β) levels were identified using enzyme-linked immunosorbent assay. Human monocyte-derived THP-1 cells were cultured and divided into the control, BLP, and BLP + UTI (10, 100, 1000 U/ml, respectively) groups. Cell supernatant and extracted proteins from cultured cells treated at different UTI concentrations (10, 100, and 1000 U/ml) were collected to evaluate the tumor necrosis factor α (TNF-α) and IL-1β levels using enzyme-linked immunosorbent assay. Western blot analysis was executed to evaluate the level of expression of nuclear factor kappa B (NF-κB), phosphorylated-IκB, IκB, phosphorylated protein 38, and protein 38.

Results:
The CLP group exhibited elevated levels of creatine kinase-myoglobin binding, aspartate aminotransferase, and IL-1β. However, after the administration of UTI, these levels decreased. UTI treatment proved effective in improving inflammatory injury in the heart and lung tissues in septic mice. Furthermore, it reduced the release of inflammatory cytokines in THP-1 cells stimulated by BLP. Additionally, treatment with UTI decreased the activity of NF-κB and upregulated the protein expression levels of phosphorylated-IκB and phosphorylated protein 38 in THP-1 cells induced by BLP.

Conclusions:
UTI can effectively inhibit BLP-induced activation of the NF-κB/IκB and protein 38/ mitogen-activated protein kinase signaling pathways, thereby suppressing the inflammatory response and improving sepsis.
REFERENCES (31)
1.
Evans L, Rhodes A, Alhazzani W, et al. (2021): Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49: e1063-e1143.
 
2.
Chousterman BG, Swirski FK, Weber GF (2017): Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol 39: 517-528.
 
3.
Uemura K, Murakami Y, Hayashidani Y, et al. (2008): Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. J Surg Oncol 98: 309-313.
 
4.
Linder A, Russell JA (2014): An exciting candidate therapy for sepsis: ulinastatin, a urinary protease inhibitor. Intensive Care Med 40: 1164-1167.
 
5.
Fukushima H, Oguchi T, Sato H, et al. (2021): Ulinastatin attenuates protamine-induced cardiotoxicity in rats by inhibiting tumor necrosis factor alpha. Naunyn Schmiedebergs Arch Pharmacol 394: 373-381.
 
6.
Li ST, Dai Q, Zhang SX, et al. (2018): Ulinastatin attenuates LPS-induced inflammation in mouse macrophage RAW264.7 cells by inhibiting the JNK/NF-κB signaling pathway and activating the PI3K/Akt/Nrf2 pathway. Acta Pharmacol Sin 39: 1294-1304.
 
7.
Zhang X, Zhu Z, Jiao W, et al. (2019): Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulm Med 19: 196.
 
8.
Travassos LH, Girardin SE, Philpott DJ, et al. (2004): Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 5: 1000-1006.
 
9.
Akira S, Takeda K (2004): Toll-like receptor signaling. Nat Rev Immunol 4: 499-511.
 
10.
Baker CC, Chaudry IH, Gaines HO, Baue AE (1983): Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94: 331-335.
 
11.
Drechsler S, Osuchowski M (2021): Cecal ligation and puncture. Methods Mol Biol 2321: 1-8.
 
12.
Song C, Zhang Y, Pei Q, et al. (2022): HSP70 alleviates sepsis-induced cardiomyopathy by attenuating mitochondrial dysfunction-initiated NLRP3 inflammasome-mediated pyroptosis in cardiomyocytes. Burns Trauma 10: tkac043.
 
13.
Yu H, Lin L, Zhang Z, et al. (2020): Targeting NF-kappaB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduct Target Ther 5: 209.
 
14.
Li P, Chen XR, Xu F, et al. (2018): Alamandine attenuates sepsis-associated cardiac dysfunction via inhibiting MAPKs signaling pathways. Life Sci 206: 106-116.
 
15.
Arina P, Singer M (2021): Pathophysiology of sepsis. Curr Opin Anesthesiol 34: 77-84.
 
16.
Akira S, Uematsu S, Takeuchi O (2006): Pathogen recognition and innate immunity. Cell 124: 783-801.
 
17.
Moreira A, Lebbé C, Heinzerling L (2021): MAPK blockade, toxicities, pathogenesis and management. Curr Opin Oncol 33: 139-145.
 
18.
Lu Q, Liu Z, He W, Chu X (2021): Protective effects of ulinastatin on rats with acute lung injury induced by lipopolysaccharide. Bioengineered 15: 1987083.
 
19.
Qiu J, Xiao X, Gao X, Zhang Y (2021): Ulinastatin protects against sepsis induced myocardial injury by inhibiting NLRP3 inflammasome activation. Mol Med Rep 24: 730.
 
20.
Lopez-Castejon G, Brough D (2011): Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 22: 189-195.
 
21.
Malik A, Thirumala-Devi K (2018): Function and regulation of IL-1β in inflammatory diseases and cancer. Immunol Rev 281: 124-137.
 
22.
Cao YZ, Tu YY, Chen X, et al. (2012): Protective effect of Ulinastatin against murine models of sepsis: inhibition of TNF-α and IL-6 and augmentation of IL-10 and IL-13. Exp Toxicol Pathol 64: 543-547.
 
23.
Yang H, Zhang Z (2021): Sepsis-induced myocardial dysfunction: the role of mitochondrial dysfunction. Infamm Res 70: 379-387.
 
24.
Wang JH, Doyle M, Manning BJ, et al. (2002): Induction of bacterial lipoprotein tolerance is associated with suppression of Toll-like receptor-2 expression. J Biol Chem 277: 36068.
 
25.
Lakhani SA, Bogue CW (2003): Toll-like receptor signaling in sepsis. Curr Opin Pediatr 15: 278-282.
 
26.
Weighardt H, Holzmann B (2007): Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 212: 715-722.
 
27.
Cronin JG, Turner ML, Goetze L, et al. (2012): Toll-like receptor 4 and MYD88-dependent signaling mechanisms of the innate immune system are essential for the response to lipopolysaccharide by epithelial and stromal cells of the bovine endometrium. Biol Reprod 86: 51.
 
28.
Liu J, Xiang J, Li X, et al. (2017): NF-κB activation is critical for bacterial lipoprotein tolerance-enhanced bactericidal activity in macrophages during microbial infection. Sci Rep 7: 40418.
 
29.
Peng T, Zhang T, Lu X, Feng Q (2009): JNK1/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia. Cardiovasc Res 81: 733-741.
 
30.
Gao J, Zhao F, Yi S, et al. (2022): Protective role of crocin against sepsis-induced injury in the liver, kidney and lungs via inhibition of p38 MAPK/NF-κB and Bax/Bcl-2 signalling pathways. Pharm Biol 60: 543-552.
 
31.
Ru JY, Xu HD, Shi D (2016): Blockade of NF-κB and MAPK pathways by ulinastatin attenuates wear particle-stimulated osteoclast differentiation in vitro and in vivo. Biosci Rep 36: e00399.
 
eISSN:1644-4124
ISSN:1426-3912
Journals System - logo
Scroll to top